Previously Treated Childhood Rhabdomyosarcoma
21
0
0
20
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
5%
1 trials in Phase 3/4
50%
10 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (21)
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma
Biomarkers in Patients With Advanced Rhabdomyosarcoma
Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Irinotecan in Treating Children With Refractory Solid Tumors
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors